NCT02655614 - A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

GDC-0134

GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.

DRUG

Placebo

Placebo matching to GDC-0134

DRUG

Rabeprazole

Rabeprazole 20 mg twice daily orally

DRUG

Midazolam

2mg of liquid formulation of midazolam orally

DRUG

Caffeine

100 mg tablet or solution of caffeine orally

Trial Locations (10)

Johns Hopkins University School of Medicine, Baltimore

Wake Research Associates, Raleigh

The Emory ALS Clinic, Atlanta

Mayo Clinic Hospital - Florida, Jacksonville

University of Miami Miller School of Medicine, Miami

New Orleans Center for Clinical Research, Knoxville

Forbes Norris Mda/als Ctr; Research Center, San Francisco

Massachusetts General Hospital, Boston

MUCH - Montreal Neurological Institute & Hospital, Montreal

UMC Utrecht, Utrecht